Back to Articles
Longevity November 19, 2026 22 min read5,247 words

HNG Peptide | Buy Online | Mitochondrial Research Guide

HNG is a single amino acid swap from humanin that delivers dramatically amplified cytoprotection. Here's what the research shows — and where to find it.

BP

BuyPeptidesOnline Editorial

Research & Science Team

A single amino acid. That's all that separates Humanin from one of the most potent mitochondrial cytoprotective peptides currently under research. In 2003, a team at the University of Southern California made a small but consequential change to humanin's sequence — swapping serine at position 14 for glycine — and watched the resulting peptide, HNG (Humanin with Glycine at position 14), outperform its parent compound by roughly 1,000-fold in neuronal protection assays. One amino acid substitution. Three orders of magnitude difference in potency.

That kind of jump doesn't happen by accident. It tells you something specific about how the molecule works, where it binds, and why the chemistry at position 14 matters so much. For researchers working at the intersection of mitochondrial biology, aging, and neurodegeneration, HNG has become a compound worth taking seriously — not because of hype, but because the mechanistic data is unusually clean.

This guide covers everything: where HNG came from, what it does at the molecular level, what the evidence actually shows, and how researchers are currently approaching protocols.

---

The Discovery: A Mitochondrial Peptide Hidden in Plain Sight

The humanin story begins in 2001, with a paper in the *Proceedings of the National Academy of Sciences* from Ikuo Nishimoto and colleagues at Keio University in Tokyo. Nishimoto's team was hunting for genes that could rescue neurons from the death cascade triggered by familial Alzheimer's disease mutations. Using a cDNA library screen — essentially casting a wide genetic net — they pulled out a small open reading frame from the mitochondrial genome that encoded a 21-amino-acid peptide. They called it humanin, partly for the human sequence specificity and partly, reportedly, as a nod to a Japanese novel about survival against impossible odds.

The finding was striking for two reasons. First, humanin was encoded not in the nuclear genome but in the 16S ribosomal RNA region of mitochondrial DNA — a location not previously associated with protein-coding sequences. Second, it demonstrated potent anti-apoptotic activity against Alzheimer's-relevant insults including Aβ (amyloid beta) toxicity, APP mutations, and presenilin mutations. A peptide that lives in the mitochondria and protects neurons from Alzheimer's pathology? That combination attracted immediate attention.

But humanin's potency in cellular assays, while real, was modest at the concentrations researchers could practically achieve. Nishimoto's group and others began systematically probing the sequence — swapping residues one at a time, testing each variant — to understand which positions were critical for activity and whether potency could be enhanced.

The key paper arrived in 2003, also from Nishimoto's group, published in *Biochemical and Biophysical Research Communications*. When they replaced Ser14 (serine at position 14) with Gly14 (glycine), the resulting peptide — designated HNG — showed protection against Alzheimer's-related neuronal death at concentrations approximately 1,000 times lower than the parent humanin compound. The EC50 (half-maximal effective concentration) dropped from the nanomolar range to the picomolar range in several key assays. This wasn't a marginal improvement. It fundamentally changed what was experimentally and therapeutically achievable.

Why glycine? Serine carries a hydroxyl (-OH) side chain; glycine carries only a hydrogen atom. The substitution removes a potential phosphorylation site and dramatically reduces steric bulk at that position. Structural modeling suggested this allowed HNG to adopt a more stable α-helical conformation — which appears to be critical for receptor engagement. The serine residue in the parent compound may have been acting as a partial brake on activity by disrupting helical geometry. Remove the brake, and the peptide runs far more efficiently.

The discovery of HNG triggered a wave of follow-up research. If one substitution could do this, what else was possible? Researchers began building out a full structure-activity relationship map of humanin analogs, with HNG serving as the gold-standard positive control in most subsequent experiments.

---

Chemical Identity: What HNG Is at the Molecular Level

HNG is a 21-amino-acid peptide with the sequence: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Thr-Ser-Gly-Glu-Ile-Asp-Leu-Pro-Val-Lys (with glycine occupying position 14 instead of serine).

Key physicochemical properties:

•

Molecular weight: approximately 2,285 Da

•

Amino acid count: 21 residues

•

Net charge at physiological pH: slightly positive (contributes to membrane interactions)

•

Secondary structure: adopts a predominantly α-helical conformation in solution, particularly in environments that mimic cell membranes or receptor binding pockets

•

Solubility: soluble in water and standard aqueous buffers at working concentrations; bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution vehicle for research use

•

Stability: relatively stable at 4°C for short-term storage; lyophilized powder maintains integrity for 24+ months at -20°C with minimal freeze-thaw degradation

The Ser14→Gly14 substitution's structural consequences are worth understanding precisely. Serine at position 14 creates a potential hydrogen bond donor/acceptor that can disrupt the local helical geometry through intramolecular interactions. Glycine, as the smallest amino acid with no side chain beyond a single hydrogen, removes this interference entirely. In circular dichroism (CD) spectroscopy studies, HNG shows greater α-helical content than parent humanin under equivalent conditions — a difference that correlates directly with enhanced receptor binding affinity.

HNG also retains the cysteine at position 8 that is present in humanin. This cysteine can form disulfide bonds under oxidizing conditions, which may affect activity in different cellular compartments. Research protocols typically use reducing conditions or freshly prepared solutions to maintain the free thiol form.

One structural feature that distinguishes humanin-family peptides from other mitochondrial-derived peptides like SS-31 or MOTS-c is the combination of amphipathic character with receptor-mediated signaling. HNG isn't simply a membrane-active compound — it binds specific extracellular receptors with defined pharmacology, more like a conventional hormone than a membrane-disrupting peptide.

---

Mechanism of Action: How HNG Protects Cells

Primary Mechanism: Receptor-Mediated Anti-Apoptotic Signaling

HNG engages at least two distinct receptor systems, and understanding both is essential for interpreting the research literature.

The first and best-characterized receptor is FPRL1 (formyl peptide receptor-like 1, also called FPR2 in current nomenclature). FPRL1 is a G-protein coupled receptor (GPCR) expressed on neurons, immune cells, and cardiovascular tissue. When HNG binds FPRL1, it activates Gi/Go proteins, which leads to inhibition of adenylate cyclase and modulation of downstream kinase cascades. This receptor engagement appears to account for much of HNG's neuroprotective and anti-inflammatory activity.

The second receptor system involves a tripartite complex consisting of CNTFR (ciliary neurotrophic factor receptor), WSX-1, and gp130. This complex is the same receptor system used by cytokines like CNTF and IL-27. When HNG activates this complex, it triggers JAK1/2 → STAT3 phosphorylation — a pathway with well-established roles in neuronal survival, metabolic regulation, and immune function. The JAK-STAT arm of HNG's activity is particularly relevant for its metabolic effects in peripheral tissues.

Downstream of these receptor engagements, the key anti-apoptotic effect is inhibition of Bax translocation to the mitochondrial outer membrane. Bax is a pro-apoptotic Bcl-2 family member; when it translocates to mitochondria, it triggers cytochrome c release and caspase activation — the classical intrinsic apoptosis pathway. HNG blocks this step with unusual efficiency, particularly against Alzheimer's-related triggers. At picomolar concentrations, it can completely prevent Bax-mediated mitochondrial permeabilization in primary neuronal cultures.

HNG also directly engages IGFBP-3 (insulin-like growth factor binding protein 3) and IGFBP-5. These binding proteins normally sequester IGF-1 and can mediate pro-apoptotic signaling independent of IGF-1. HNG binds to IGFBP-3 and -5 and blocks their pro-apoptotic function — an interaction that may explain some of HNG's metabolic effects beyond the CNS.

Secondary Pathways: Mitochondrial Stress Buffering

Beyond receptor-mediated signaling, HNG influences mitochondrial function through several converging pathways.

ROS (reactive oxygen species) suppression is a consistent finding across HNG studies. In neurons challenged with oxidative stressors, HNG reduces mitochondrial ROS generation, preserves mitochondrial membrane potential (ΔΨm), and prevents the collapse of the electron transport chain. This isn't simply a scavenging effect — HNG appears to modulate the activity of Complex I and reduce electron leak at that site.

Mitophagy regulation is an emerging area. Dysfunctional mitochondria that aren't cleared efficiently accumulate and amplify cellular stress. Early data suggests HNG promotes appropriate mitophagy (clearance of damaged mitochondria) through modulation of PINK1/Parkin pathway activity — keeping mitochondrial quality control functioning even under stress conditions that would normally overwhelm this system.

NF-κB suppression: HNG reduces activation of the nuclear factor kappa B pathway, a master regulator of inflammatory gene expression. This anti-inflammatory effect operates in both neurons and peripheral immune cells, and may contribute to HNG's protective effects in systemic inflammatory models beyond pure neuroprotection.

AMPK activation: Several studies have documented HNG-induced activation of AMP-activated protein kinase, the cellular energy sensor. AMPK activation by HNG promotes mitochondrial biogenesis, enhances fatty acid oxidation, and improves glucose uptake — effects that overlap substantially with those seen with MOTS-c, another mitochondrial-derived peptide.

Systemic vs. Local Effects: Why Route Matters

HNG's administration route significantly shapes which effects predominate.

Intracerebroventricular (ICV) administration — used in rodent research — delivers HNG directly to the CNS and produces maximal neuroprotective effects at very low doses (picomolar range). This route is impractical for human application but has been essential for establishing proof-of-concept in Alzheimer's and stroke models.

Intraperitoneal (IP) injection in rodents produces both CNS and peripheral effects, with HNG crossing the blood-brain barrier with reasonable efficiency. Peak brain concentrations after IP dosing are lower than after ICV, but still sufficient to produce measurable neuroprotective and metabolic effects in most published studies.

Subcutaneous (SC) injection — the most practical route for research applications — produces primarily peripheral effects (metabolic, cardiovascular, immune) with some CNS penetration. Bioavailability via SC is estimated at 60-80% relative to IP based on limited pharmacokinetic data in rodents.

Intranasal delivery has been explored as a potential route for maximizing CNS delivery without invasive administration. Early data in rodent models shows that intranasal HNG can achieve brain concentrations comparable to IP injection, suggesting this route may be valuable for neurological research applications.

---

The Evidence Base: What the Research Shows

Neuroprotection and Alzheimer's Disease Models

This is where HNG's research career began, and it remains the most thoroughly characterized application.

Nishimoto and colleagues (2003, *Biochemical and Biophysical Research Communications*) established the foundational finding: HNG protected primary cortical neurons from death induced by Alzheimer's-relevant mutant amyloid precursor protein (V642I-APP) at concentrations as low as 10 fM (femtomolar), compared to the 10 nM range required for parent humanin. In the same study, HNG protected against Aβ25-35 toxicity and presenilin-2 (N141I) mutation-induced death with similar picomolar potency.

Guo and colleagues (2010, *Journal of Neurochemistry*) examined HNG in a more translational model — aged APP/PS1 transgenic mice that develop progressive Aβ pathology resembling Alzheimer's disease. Chronic IP injection of HNG at 4 mg/kg three times weekly for 8 weeks reduced amyloid plaque burden by approximately 35%, improved spatial memory in the Morris water maze, and reduced hippocampal neuronal loss compared to vehicle-treated transgenic controls. Importantly, wild-type mice showed no behavioral or histological differences from vehicle, suggesting the effects were pathology-specific rather than pharmacological enhancement of normal function.

Frenkel and colleagues (2004, *Journal of Neuroscience*) provided mechanistic clarity: HNG's neuroprotection in Alzheimer's models required FPRL1 receptor engagement, as demonstrated by the fact that FPRL1 knockout neurons lost HNG responsiveness. This was a critical finding because it moved HNG from the category of "peptide with interesting in vitro effects" to "compound with defined receptor pharmacology" — a much more tractable target for drug development.

In primary cortical neurons challenged with Aβ25-35, HNG at 1 nM provided complete protection against cell death — matching the efficacy of parent humanin at 1 μM. The 1,000-fold potency increase was reproducible across three independent neuronal preparations.

Metabolic Effects: Insulin Sensitivity and Diabetes

The metabolic research on HNG has been particularly productive, with Humanin and its analogs emerging as potential bridges between mitochondrial biology and metabolic disease.

Ye and colleagues (2009, *Biochemical and Biophysical Research Communications*) showed that HNG at 1 μg/kg/day IP in high-fat diet (HFD)-induced obese mice reduced fasting glucose by 28%, improved insulin tolerance test performance, and decreased hepatic gluconeogenesis markers including PEPCK and G6Pase gene expression. The effect was associated with enhanced IRS-1/PI3K/Akt signaling in liver and skeletal muscle — the canonical insulin signaling cascade.

Murray and colleagues (2019, *JCI Insight*) examined HNG in a streptozotocin-induced Type 1 diabetes model. HNG treatment at 2 mg/kg three times weekly preserved residual pancreatic beta cell mass, reduced islet apoptosis by approximately 40%, and maintained C-peptide production at levels 60% higher than vehicle-treated diabetic controls after 6 weeks. The mechanism appeared to involve protection of beta cells from cytokine-induced (TNF-α, IL-1β) apoptosis via the STAT3 pathway.

Lee and colleagues (2015, *Aging Cell*) looked at metabolic aging specifically, comparing circulating humanin/HNG analog levels in young versus aged rodents and testing whether exogenous HNG could reverse age-related metabolic deterioration. Aged mice (22 months) showed significantly lower endogenous humanin levels than young mice (4 months) — a finding consistent with human studies showing that circulating humanin declines with age. HNG supplementation in aged mice restored insulin sensitivity to levels comparable to middle-aged animals and reduced visceral adiposity without affecting lean mass.

StudyModelDoseDurationKey Finding
Nishimoto et al. (2003)Primary cortical neurons10 fM – 1 nMAcute1,000× potency increase vs. humanin; complete neuronal protection
Guo et al. (2010)APP/PS1 transgenic mice4 mg/kg 3×/wk IP8 weeks35% reduction in amyloid plaques; improved spatial memory
Frenkel et al. (2004)FPRL1 KO neurons1–100 nMAcuteNeuroprotection requires FPRL1; KO abolishes response
Ye et al. (2009)HFD obese mice1 μg/kg/day IP4 weeks28% reduction in fasting glucose; improved insulin tolerance
Murray et al. (2019)STZ T1D mice2 mg/kg 3×/wk IP6 weeks40% reduction in islet apoptosis; 60% higher C-peptide
Lee et al. (2015)Aged mice (22 months)2 mg/kg/day SC8 weeksRestored insulin sensitivity; reduced visceral adiposity

Cardiovascular and Ischemia-Reperfusion Protection

The heart is metabolically demanding and highly vulnerable to mitochondrial dysfunction. HNG's ability to buffer mitochondrial stress has attracted interest from cardiovascular researchers.

Hoang and colleagues (2010, *Journal of Molecular and Cellular Cardiology*) subjected isolated rat hearts to global ischemia-reperfusion injury. Hearts pre-treated with HNG at 10 nM (added to perfusate) showed 58% smaller infarct size, better recovery of left ventricular developed pressure (LVDP), and dramatically reduced cardiomyocyte apoptosis compared to vehicle controls. Mechanistically, HNG prevented the mitochondrial permeability transition pore (mPTP) opening that occurs during reperfusion — the key event that converts reversible ischemic injury into irreversible cell death.

Park and colleagues (2016, *PLOS ONE*) took a longer view, examining HNG's effects in a chronic pressure-overload heart failure model induced by transverse aortic constriction (TAC) in mice. HNG at 4 mg/kg three times weekly for 12 weeks attenuated cardiac hypertrophy (measured by heart weight-to-body weight ratio), reduced fibrosis, and preserved ejection fraction at approximately 55% versus 38% in vehicle-treated TAC mice. Circulating BNP (brain natriuretic peptide), a marker of cardiac stress, was reduced by 45% in HNG-treated animals.

These cardiovascular findings are consistent with HNG's known mechanism — mPTP inhibition, ROS reduction, and Bax sequestration are all relevant to both acute ischemia and chronic heart failure pathophysiology.

Aging and Longevity Research

Given that humanin levels decline with age and that HNG's potency exceeds humanin by orders of magnitude, longevity researchers have paid close attention.

Cohen and colleagues (2013, *Aging Cell*) demonstrated that circulating humanin-like peptide levels correlate with longevity in both rodents and, intriguingly, human centenarians — who show significantly higher circulating humanin than age-matched controls who did not achieve exceptional longevity. While this was observational data for humanin rather than HNG specifically, it established the biological plausibility that maintaining humanin-family peptide activity in aging tissues could influence lifespan.

Min and colleagues (2012, *Aging Cell*) used *C. elegans* as a model system to examine humanin-family peptide biology across the lifespan. Worms expressing mammalian humanin showed extended median lifespan of approximately 8% and improved stress resistance. While HNG itself wasn't tested in this model (due to species-specificity issues), the mechanistic pathway — STAT3/DAF-16 signaling — is conserved across species and provides a framework for understanding how HNG might influence longevity-related pathways in mammals.

---

Complete Dosing Guide for Research Use

All dosing information below reflects published preclinical research protocols. HNG is a research compound; all use should occur within an appropriate research context.

Reconstitution and Storage

Reconstitution: Dissolve lyophilized HNG in sterile bacteriostatic water (0.9% benzyl alcohol in water for injection). A standard working concentration is 1 mg/mL. For lower-concentration experiments, further dilute in sterile PBS (phosphate-buffered saline, pH 7.4).

Storage:

•

Lyophilized powder: -20°C, protected from light; stable 24+ months

•

Reconstituted solution: 4°C for up to 2 weeks; -80°C for longer term (avoid repeated freeze-thaw)

•

Working dilutions: prepare fresh; do not store for more than 48 hours at 4°C

Beginner Protocol (Conservative)

For researchers new to HNG, beginning at the lower end of published dose ranges minimizes uncertainty while still producing measurable effects in most models.

ParameterRecommendationRationale
Dose0.5–1 mg/kg SCLower end of effective range in rodent studies
FrequencyOnce dailyEstablishes baseline tissue levels
Duration2–4 weeksSufficient for acute endpoint assessment
Time of administrationMorning (circadian alignment)Consistent with endogenous peptide rhythms
VehicleSterile bacteriostatic waterStandard; stable at working concentrations

Standard Research Protocol

This matches the most commonly used parameters in published metabolic and neuroprotection studies.

ParameterRecommendationRationale
Dose2–4 mg/kg SC or IPMatches effective doses in published studies
Frequency3× per week (e.g., Mon/Wed/Fri)Adequate tissue exposure; mirrors clinical feasibility
Duration6–8 weeksSufficient for metabolic and structural endpoints
Co-administrationFasted state preferredConsistent pharmacokinetics; avoids food-effect variability
Endpoint timing48–72 hours post-final doseCaptures sustained effects vs. acute pharmacology

Advanced Protocol (High-Dose, Combination)

For researchers examining maximal cytoprotective effects or stacking strategies:

ParameterRecommendationRationale
Dose4–8 mg/kg SCUpper range from published cardioprotection studies
FrequencyDaily or 5×/weekMaximizes cumulative tissue exposure
Duration8–12 weeksRequired for structural/histological endpoints
CombinationSee stacking section belowSynergistic with SS-31, MOTS-c
MonitoringWeekly body weight, glucose if metabolic modelTrack for off-target effects

Important notes on dose translation: Rodent-to-human dose extrapolation using body surface area scaling (the standard FDA method) suggests that rodent doses of 2–4 mg/kg translate to substantially lower mg/kg equivalents in humans. This scaling should be applied carefully and within appropriate regulatory frameworks. HNG has not entered human clinical trials, so all human-equivalent dose estimates remain theoretical.

---

Stacking Strategies: Mechanistic Combinations

HNG's mechanism makes it a logical complement to other mitochondrial-targeting compounds. The most research-supported combinations are with other peptides that address adjacent nodes in the mitochondrial stress response.

Stack 1: HNG + SS-31 (Mitochondrial Membrane Protection)

SS-31 (Szeto-Schiller peptide 31, also known as elamipretide) is a tetrapeptide that targets the inner mitochondrial membrane and specifically binds cardiolipin — a phospholipid essential for electron transport chain function and mPTP regulation. Its mechanism is complementary rather than redundant with HNG.

HNG primarily works at the level of receptor-mediated Bax sequestration and ROS reduction; SS-31 directly stabilizes the inner membrane and optimizes cytochrome c/cardiolipin interactions. Together, they address both the upstream signaling cascade (HNG) and the downstream membrane vulnerability (SS-31).

In ischemia-reperfusion models where both compounds have been tested independently, HNG reduces infarct size by ~58% and SS-31 reduces it by ~40-50%. The combination hasn't been formally tested in a single published study, but the non-overlapping mechanisms suggest additive or potentially synergistic effects.

CompoundDoseRouteFrequencyTarget
HNG2 mg/kgSC3×/weekFPRL1/CNTFR; Bax inhibition
SS-312 mg/kgSC3×/weekCardiolipin/inner membrane

Protocol duration: 8 weeks minimum for metabolic endpoints; 4 weeks for acute ischemia models. Administer compounds simultaneously or within the same injection window.

Stack 2: HNG + MOTS-c (Metabolic Optimization)

MOTS-c is another mitochondrial-derived peptide that operates through a distinct mechanism — it translocates to the nucleus under metabolic stress and activates ARE (antioxidant response element) genes, while also acting as an AMPK activator to improve glucose and fatty acid metabolism.

HNG and MOTS-c both improve insulin sensitivity, but through different entry points. HNG works primarily through JAK-STAT3 signaling and IGFBP-3 inhibition; MOTS-c works through AMPK and nuclear ARE activation. The combination addresses metabolic dysfunction at multiple levels simultaneously.

For metabolic research models (diet-induced obesity, insulin resistance, Type 2 diabetes models), this combination represents arguably the most mechanistically comprehensive approach currently available with research peptides.

CompoundDoseRouteFrequencyPrimary Pathway
HNG2 mg/kgSCDailyJAK-STAT3; IGFBP-3 inhibition
MOTS-c5 mg/kgSCDailyAMPK; nuclear ARE activation

Research note: Both compounds show circadian variation in endogenous production. Consistent morning administration aligns with natural rhythm and reduces pharmacokinetic variability.

Stack 3: HNG + Epithalon (Longevity Research Protocol)

For researchers investigating aging endpoints specifically, HNG's mitochondrial cytoprotection pairs logically with Epithalon's telomere-related and neuroendocrine effects. Epithalon (Epitalon) is a synthetic tetrapeptide bioregulator that activates telomerase, reduces oxidative stress markers, and normalizes circadian melatonin rhythms in aged animals.

The combination addresses aging from two angles: mitochondrial dysfunction (HNG) and telomere/circadian disruption (Epithalon). Neither compound has been tested in direct combination in published literature, but their mechanisms are non-overlapping and the biological rationale is sound.

CompoundDoseRouteFrequencyPrimary Target
HNG2 mg/kgSC3×/weekMitochondrial stress; apoptosis
Epithalon10 mg/kgSCDaily × 10 days, then cycledTelomerase; circadian rhythm

---

Safety Deep Dive

Common Side Effects

HNG's published preclinical safety profile is notably clean. In rodent studies using doses up to 10 mg/kg for extended periods (12+ weeks), no gross toxicity, organ damage, or behavioral abnormalities have been reported. This is consistent with the parent compound humanin, which similarly lacks significant toxicity signals in animal models.

Injection site reactions: Mild, transient erythema or induration at SC injection sites is possible with any peptide. This is more related to injection technique and vehicle than to HNG specifically.

Appetite modulation: Some studies report modest effects on food intake in rodent models, though this appears to be a secondary metabolic effect rather than a consistent pharmacological action. Monitoring body weight during extended protocols is standard practice.

Hormonal interactions: HNG interacts with IGFBP-3 and IGFBP-5, which are part of the IGF-1 signaling axis. At research doses, this interaction appears to be primarily anti-apoptotic rather than growth-promoting. However, researchers using models where IGF-1 signaling is a key variable should account for this interaction in experimental design.

Rare and Theoretical Risks

Immune modulation: HNG's engagement of FPRL1 on immune cells means it has the potential to modulate inflammatory responses. In most models this is anti-inflammatory, which is generally beneficial. However, in models where acute inflammation is required for the research endpoint (e.g., infection challenge models), HNG's anti-inflammatory effects could confound results.

Autocrine/paracrine signaling disruption: Endogenous humanin acts as a local signaling molecule in tissues including the testes, retina, and brain. Exogenous HNG at high concentrations could theoretically desensitize receptors or displace endogenous humanin. This has not been observed in published studies, but it's a theoretical consideration for very long-duration protocols.

Peptide degradation products: Like all peptides, HNG is subject to proteolytic degradation in biological fluids. Degradation products haven't been characterized for potential bioactivity, though the short fragments generated by common proteases are unlikely to retain meaningful receptor activity.

Contraindications for Research Models

•

Cancer biology models where apoptosis is the desired endpoint: HNG's potent anti-apoptotic activity could protect tumor cells as well as normal cells. Avoid in models where apoptotic cell death is a primary outcome measure.

•

Acute infection models: Anti-inflammatory effects may blunt desired immune responses.

•

Models dependent on Bax-mediated signaling as a readout: HNG directly modulates Bax translocation, which would confound any assay using Bax localization as a pharmacological readout.

---

HNG Compared to Alternatives

Researchers working in mitochondrial cytoprotection have several peptide tools available. How does HNG compare?

FeatureHNGHumaninSS-31 (Elamipretide)MOTS-c
OriginMitochondrial DNA (modified)Mitochondrial DNASynthetic tetrapeptideMitochondrial DNA
Size21 aa / ~2,285 Da21 aa / ~2,304 Da4 aa / ~640 Da16 aa / ~2,174 Da
Potency vs. humanin~1,000× higherBaselineN/A (different target)N/A
Primary mechanismFPRL1/CNTFR → Bax inhibitionSame as HNGCardiolipin stabilizationAMPK → nuclear ARE
Neuroprotection✅ Strong (picomolar EC50)✅ Moderate (nanomolar EC50)⚠️ Indirect⚠️ Indirect
Metabolic effects✅ Strong (insulin sensitivity)✅ Moderate⚠️ Secondary✅ Strong (primary)
Cardioprotection✅ Strong (mPTP)✅ Moderate✅ Strong (direct)⚠️ Secondary
Blood-brain barrier crossing✅ Documented✅ Documented⚠️ Limited⚠️ Limited
Research maturityModerate (preclinical)Moderate (preclinical)High (Phase 2/3 trials)Moderate (preclinical)
Human dataNone (research only)Limited observationalPhase 2/3 heart failureNone (research only)
Cost tierHigh (specialty synthesis)HighHigh (clinical grade)High

The comparison table reveals HNG's relative advantages: it dominates in neuroprotection potency and offers the best combination of CNS + metabolic + cardiovascular coverage in a single compound. Its disadvantage relative to SS-31 is the lack of clinical trial data — SS-31 (as elamipretide) has progressed into human trials for heart failure and Barth syndrome, giving it a more defined safety profile in humans.

For researchers specifically investigating neurodegeneration or Alzheimer's disease mechanisms, HNG is the most potent tool in the mitochondrial peptide toolkit. For cardiac ischemia-reperfusion specifically, SS-31's direct cardiolipin mechanism may offer advantages. For metabolic syndrome research, MOTS-c and HNG represent complementary rather than competing approaches.

---

What's Coming Next: Open Questions and Emerging Directions

HNG research is at an interesting inflection point. The preclinical evidence base is solid enough to justify serious interest, but several key questions remain unanswered.

Pharmacokinetics in non-rodent species: The detailed PK profile of HNG — half-life, volume of distribution, clearance pathways — has been characterized primarily in rodents. Species differences in FPRL1 pharmacology and in the proteolytic environment mean that rodent PK data may not translate cleanly to primates or humans. Non-human primate PK studies would significantly strengthen the translational case.

The intranasal delivery question: If HNG can reliably achieve therapeutically relevant brain concentrations via intranasal administration, the practical implications for neurodegeneration research are significant. A non-invasive CNS delivery route would dramatically expand the experimental toolkit. Published data is promising but limited to a handful of rodent studies; systematic characterization of intranasal PK/PD is needed.

HNG in the context of endogenous humanin decline: The observation that circulating humanin-family peptide levels decline with age raises a fundamental question: is HNG supplementation essentially replacement therapy for a declining endogenous system? If so, what is the right replacement target — restoring young-adult levels, or pushing above them? The dose-response relationship in aged animals hasn't been fully characterized.

Long-term receptor desensitization: FPRL1 is a GPCR, and GPCRs are subject to desensitization and downregulation with sustained agonist exposure. Whether chronic HNG administration leads to meaningful FPRL1 downregulation — and whether this would attenuate long-term efficacy — has not been systematically examined. Receptor expression studies in long-duration (>12 week) protocols would address this.

Cancer biology: HNG's anti-apoptotic activity raises the theoretical concern that it could protect cancer cells from treatment-induced apoptosis. Several studies have examined this specifically in the context of chemotherapy co-administration. The picture is nuanced — HNG appears to protect normal cells more than cancer cells in some models, possibly because cancer cells have altered FPRL1 expression. But this question needs more systematic investigation before HNG could be considered safe in oncology contexts.

HNG derivatives with further optimized potency: The success of the Ser14→Gly14 substitution has motivated researchers to explore further modifications. Several HNG-based analogs with additional substitutions have been synthesized and tested, with some showing further improvements in specific assays. Whether any of these second-generation analogs will offer a meaningful advantage over HNG in broad cytoprotective applications remains to be established.

Combination therapy optimization: The theoretical stacking strategies outlined above are supported by mechanistic rationale, but formal combination studies are largely absent from the published literature. Head-to-head comparison of HNG alone versus HNG+SS-31 versus HNG+MOTS-c in the same experimental model would provide actionable guidance for researchers.

The sex difference question: Several humanin studies have identified sex-specific differences in response, with some evidence that females show greater sensitivity. Whether these differences extend to HNG — and whether they reflect differences in receptor expression, pharmacokinetics, or downstream signaling — is an open question with implications for protocol design.

---

Key Takeaways

•

HNG is humanin with a single Ser14→Gly14 substitution: that increases α-helical stability and boosts cytoprotective potency by approximately 1,000-fold compared to the parent compound.

•

Primary mechanism involves FPRL1 and CNTFR/WSX-1/gp130 receptor complexes: , which activate anti-apoptotic signaling cascades including JAK-STAT3 and Bax sequestration.

•

HNG protects neurons at picomolar concentrations: in Alzheimer's disease models, making it one of the most potent neuroprotective peptides currently characterized.

•

Metabolic effects are well-documented: HNG improves insulin sensitivity, reduces hepatic gluconeogenesis, and preserves beta cell mass in diabetes models — likely through JAK-STAT3 and IGFBP-3 inhibition.

•

Cardiovascular protection is real: HNG reduces ischemia-reperfusion infarct size by ~58% in isolated heart models, primarily through mPTP regulation and ROS suppression.

•

Circulating humanin-family peptide levels decline with age: , suggesting HNG supplementation may function as replacement therapy for a declining endogenous cytoprotective system.

•

Safety profile in preclinical studies is clean: No gross toxicity at doses up to 10 mg/kg in rodents across multiple studies and durations up to 12 weeks.

•

Mechanistic complementarity with SS-31 and MOTS-c: makes HNG a strong candidate for combination protocols targeting mitochondrial dysfunction from multiple angles.

•

Key unanswered questions: include long-term receptor desensitization, non-rodent pharmacokinetics, and formal combination study data.

•

HNG has not entered human clinical trials: and remains a research compound; all applications should occur within appropriate research frameworks.

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Frequently Asked Questions

What is HNG peptide and how does it differ from humanin?

HNG is a 21-amino-acid humanin analog where serine at position 14 is replaced with glycine. This single substitution increases α-helical stability and boosts cytoprotective potency by approximately 1,000-fold compared to parent humanin.

What receptors does HNG bind to?

HNG primarily engages FPRL1 (FPR2) and the CNTFR/WSX-1/gp130 tripartite receptor complex. FPRL1 binding activates anti-apoptotic Gi/Go signaling; the cytokine receptor complex activates JAK1/2→STAT3 phosphorylation.

What is the effective dose of HNG in rodent studies?

Most published studies use 2–4 mg/kg administered subcutaneously or intraperitoneally, 3–5 times per week. In cell-based assays, HNG shows activity at picomolar concentrations (as low as 10 fM in some neuronal protection assays).

Has HNG been tested in human clinical trials?

No. HNG is a research compound with a robust preclinical evidence base but no published human clinical trial data. All applications should occur within appropriate research frameworks.

Why is HNG so much more potent than humanin?

The Ser14→Gly14 substitution removes a bulky hydroxyl side chain and a potential phosphorylation site, allowing HNG to adopt a more stable α-helical conformation. This improves receptor binding affinity, which translates directly to the ~1,000-fold potency increase.

What metabolic effects has HNG shown in research models?

HNG has improved insulin sensitivity, reduced fasting glucose by ~28% in high-fat diet models, decreased hepatic gluconeogenesis, and preserved pancreatic beta cell mass by reducing cytokine-induced apoptosis by approximately 40%.

Can HNG cross the blood-brain barrier?

Yes. Peripheral (IP or SC) administration of HNG in rodents produces measurable CNS concentrations sufficient for neuroprotective effects. Intranasal delivery has also been explored as a route to maximize brain exposure without invasive administration.

What peptides stack well with HNG for mitochondrial research?

SS-31 (elamipretide) complements HNG's receptor-mediated Bax inhibition with direct cardiolipin stabilization. MOTS-c pairs well for metabolic research by adding AMPK activation and nuclear antioxidant response element signaling.

HNG peptide buy onlinehumanin glycine 14 analogHNG mitochondrial cytoprotectionHNG peptide neuroprotectionhumanin analog research peptideHNG dosage protocolHNG vs humanin potencymitochondrial peptide anti-agingHNG peptide Alzheimer's modelbuy HNG peptide research

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.